Professional
Added to YB: 2024-04-23
Pitch date: 2024-04-22
ALK-B.CO [bullish]
ALK-Abelló A/S
+75.45%
current return
Author Info
Mr. Market Miscalculates (mostly) shares overlooked or misunderstood small/mid-cap European companies. Sign up for the newsletter.
Company Info
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Market Cap
DKK 33.6B
Pitch Price
DKK 127.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.71
P/E
41.30
EV/Sales
6.18
Sector
Pharmaceuticals
Category
growth
ALK-Abelló A/S - $ALK-B.CO
ALK-Abelló (ALK-B.CO): Global leader in allergy prevention, owned 40% by Lundbeck Fdn. Tablets grew 15% p.a. since 2015 vs injectables 1%. Pipeline: peanut, tree pollen allergies. Mkt ~$20B growing 8%, AIT $2B at 10%. Reset in 2017: R&D, sales force investments hit margins. 2024 guide: revs +9-12%, 17-19% op margin (14% '23). Trades at 29x '24 EBIT, 5.3x sales. Peer Stallergenes taken private at 33x EBIT, 2.5x sales in '19. Risks: valuation, slow tablet adoption. Upside: food allergies, M&A.
Read full article (10 min)